Rezdiffra (resmetirom) has potential interactions with other medications. These interactions could affect how well the drug works or cause harmful effects. Rezdiffra is used in adults to treat ...
Rezdiffra has interactions with certain drugs, such as clopidogrel, atorvastatin, and gemfibrozil. Talk with your doctor to avoid potentially harmful effects from Rezdiffra interactions. Rezdiffra is ...
Rezdiffra (resmetirom) is a brand-name prescription oral tablet used to treat a certain type of liver disease. It is not a weight-loss medication. Rezdiffra was approved by the Food and Drug ...
Hosted on MSN
Madrigal signals blockbuster Rezdiffra trajectory as new patent extends exclusivity to 2045
William J. Sibold, CEO, highlighted a "productive last few months" focused on driving the launch and building for the future, noting, "Rezdiffra’s quarterly run rate now exceeds $200 million, well on ...
Madrigal Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the patent covering Rezdiffra™ (resmetirom), the only FDA-approved treatment for ...
Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral ...
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra Poster of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results